Drug Trial Radar · NCT07758218
Allogeneic iNKT Cell Therapy (agenT-797) After SCT
Last checked: Nov 20, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
22
Planned (sponsor's estimate)
Start
Nov 2026
Primary completion
Oct 2029
Study completion Oct 2029
Sponsor
- Lead sponsor
- University of Wisconsin, MadisonAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Aug 11, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Sequential
- Masking
- None
- Primary purpose
- Supportive care
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this clinical trial is to learn if agenT-797 is safe to use on people undergoing allogenic hematological stem cell transplantation (SCT). The main questions it aims to answer are: * Is agenT-797 safe to use? * What medical problems do participants have when taking agenT-797? Participants will receive an infusion of agenT-797 about 7 days after their allogenic SCT.
Conditions
- Allogenic Stem Cell Transplantation
- Myeloid Malignancies
- Lymphoid Malignancies
- Acute Myeloid Leukemia
- Chronic Myeloid Leukemia
- Myelodysplastic Syndrome
Interventions
agenT-797Drug
agenT-797 is an off-the-shelf cell therapy consisting of ≥ 95% allogeneic human unmodified iNKT cells isolated from 1 healthy donor mononuclear cell apheresis unit and expanded ex vivo.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number Of Participants With Treatment-related Adverse EventsTime frame: Baseline through Day 29 post cell infusion
- Number Of Dose-limiting ToxicitiesTime frame: Baseline through Day 29 post cell infusion
Locations
1 site in 1 country. Site status is shown where the registry gives one.
University of Wisconsin - Madison
Madison, Wisconsin · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.